Edwards Lifesciences Corp (EW)

Debt-to-equity ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Long-term debt	US$ in thousands	597,000	596,800	596,700	596,500	596,300	596,200	596,000	595,900	595,700	595,500	595,400	595,200	595,000	594,900	594,700	594,600	594,400	594,200	594,100	593,900
Total stockholders’ equity	US$ in thousands	6,650,000	6,657,500	6,375,700	5,978,000	5,806,700	6,217,800	5,943,600	5,844,900	5,835,900	5,541,300	5,133,300	4,658,400	4,574,300	4,210,300	3,839,100	3,901,100	4,148,300	3,814,800	3,500,300	3,447,500
Debt-to-equity ratio		0.09	0.09	0.09	0.10	0.10	0.10	0.10	0.10	0.10	0.11	0.12	0.13	0.13	0.14	0.15	0.15	0.14	0.16	0.17	0.17

December 31, 2023 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $597,000K ÷ $6,650,000K
= 0.09

The debt-to-equity ratio of Edwards Lifesciences Corp has been relatively stable over the past 8 quarters, ranging from 0.09 to 0.10. This indicates that the company has maintained a conservative level of debt relative to its equity, reflecting a favorable balance between using debt as a source of funding and maintaining a healthy level of equity. The consistency in this ratio suggests that Edwards Lifesciences Corp has been managing its debt levels prudently and has not significantly shifted its capital structure in recent quarters. This stability may indicate a conservative financial strategy and a lower financial risk profile for the company.